HANSOH PHARMAC. HD-00001 Price, Chart & Factor Analysis
Free Data & Analytics AccessNext earnings: Thu, Apr 1, 2027, after the market closes · estimates and history
HANSOH PHARMAC. HD-00001 Forecast
HANSOH PHARMAC. HD-00001 short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (1 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 40.0% a year, a typical one-standard-deviation range is 3.3255–3.7225 over a week, 3.1172–3.9308 over a month and 2.1147–4.9333 over a year. (Signals as of 22 Nov 2026.)
HANSOH PHARMAC. HD-00001 Price Chart
HANSOH PHARMAC. HD-00001 Factors
HANSOH PHARMAC. HD-00001 fundamentals: income statement, balance sheet & cash flow
HANSOH PHARMAC. HD-00001 reported revenue of €15.03bn and net income of €5.56bn in FY2025, the year ended 31 December 2025 — revenue up 22.6% and net income up 27.1% on the prior year. Free cash flow was €6.25bn. These figures are as reported in the filings, not restated: 5 fiscal years of history, back to December 2021.
| EUR billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 15.03 | 12.26 | 10.10 | 9.38 | 9.94 |
| Cost of revenue | 1.50 | 1.11 | 1.03 | 0.87 | 0.87 |
| Gross profit | 13.53 | 11.16 | 9.07 | 8.52 | 9.07 |
| Research & development | 3.36 | 2.70 | 2.10 | 1.69 | 1.80 |
| Operating income | 5.55 | 4.03 | 2.84 | 2.79 | 3.03 |
| EBITDA | 6.95 | 5.49 | 4.20 | 3.35 | — |
| Interest expense | 0.00 | 0.01 | 0.07 | 0.06 | 0.05 |
| Pre-tax income | 6.55 | 5.09 | 3.77 | 2.95 | 3.30 |
| Net income | 5.56 | 4.37 | 3.28 | 2.58 | 2.71 |
Download HANSOH PHARMAC. HD-00001 fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.3KY.F&statement=all&freq=a&format=csv&years=10
Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on HANSOH PHARMAC. HD-00001
Explore MacroFinance macro & markets research and analysis.
HANSOH PHARMAC. HD-00001 Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to HANSOH PHARMAC. HD-00001; 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow HANSOH PHARMAC. HD-00001’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About HANSOH PHARMAC. HD-00001 (Germany)
HANSOH PHARMAC. HD-00001 is a listed security in Germany. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is HANSOH PHARMAC. HD-00001?
What is the latest HANSOH PHARMAC. HD-00001 price?
Is HANSOH PHARMAC. HD-00001 in an uptrend?
How volatile is HANSOH PHARMAC. HD-00001?
What factors affect HANSOH PHARMAC. HD-00001?
Which trading strategies trade HANSOH PHARMAC. HD-00001?
How are HANSOH PHARMAC. HD-00001 returns analysed?
Where can I download free HANSOH PHARMAC. HD-00001 historical data?
Free HANSOH PHARMAC. HD-00001 historical data (last 10 years)
Browse or instantly download the last 10 years of HANSOH PHARMAC. HD-00001 daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.3KY.F&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 3.524 |
| 2026-11-19 | 3.69 |
| 2026-11-18 | 3.739 |
| 2026-11-17 | 3.811 |
| 2026-11-16 | 3.849 |
| 2026-11-13 | 3.92 |
| 2026-11-12 | 3.942 |
| 2026-11-11 | 3.909 |
| 2026-11-10 | 3.913 |
| 2026-11-09 | 3.877 |
About this stock
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, as well as a strategic collaboration with F. Hoffmann-La Roche Ltd for developing antibody-drug conjugate programs. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.